نتایج جستجو برای: itraconazole

تعداد نتایج: 2899  

Journal: :The American journal of medicine 1994
D W Denning J Y Lee J S Hostetler P Pappas C A Kauffman D H Dewsnup J N Galgiani J R Graybill A M Sugar A Catanzaro

BACKGROUND Invasive aspergillosis is the most common invasive mould infection and a major cause of mortality in immunocompromised patients. Response to amphotericin B, the only antifungal agent licensed in the United States for the treatment of aspergillosis, is suboptimal. METHODS A multicenter open study with strict entry criteria for invasive aspergillosis evaluated oral itraconazole (600 ...

Journal: :The Medical journal of Malaysia 2013
Jacinta Santhanam Nazmiah Nazmiah Muhammad Nazri Aziz

Resistance to antifungal agents has increased in Candida spp., especially in non-albicans species. Recent findings reported a strikingly low susceptibility in Candida spp. towards itraconazole in Malaysia. In this study, a colorimetric broth dilution method was utilized to determine the susceptibility of Candida spp. isolated in Kuala Lumpur Hospital within a six month period. A total of 82 iso...

2014

Ketoconazole is no longer available for clinical determination of worst-case victim drug-drug interaction (DDI) potential for cytochrome P450 3A (CYP3A)-substrate drugs; clarithromycin and itraconazole are the proposed replacements. Ketoconazole DDIs are described by unbound systemic exposures due to absence of carrier-facilitated hepatic uptake, but this aspect of clarithromycin and itraconazo...

2014

Ketoconazole is no longer available for clinical determination of worst-case victim drug-drug interaction (DDI) potential for cytochrome P450 3A (CYP3A)-substrate drugs; clarithromycin and itraconazole are the proposed replacements. Ketoconazole DDIs are described by unbound systemic exposures due to absence of carrier-facilitated hepatic uptake, but this aspect of clarithromycin and itraconazo...

Journal: :Journal of the European Academy of Dermatology and Venereology : JEADV 2005
A Srebrnik S Levtov R Ben-Ami S Brenner

Three weeks after completing a 4-pulse course of itraconazole for toenail onychomycosis, a 25-year-old woman patient developed severe liver crisis and required an emergency liver transplant. We report the case and discuss the use of itraconazole in onychomycosis and dermatomycoses.

Journal: :Antimicrobial agents and chemotherapy 1999
C Aguilar I Pujol J Guarro

MICs and minimum fungicidal concentrations of amphotericin B, miconazole, itraconazole, ketoconazole, fluconazole, and flucytosine against 17 isolates of Scopulariopsis spp. were determined by a broth microdilution method. All the isolates were resistant to itraconazole, fluconazole, and flucytosine, and amphotericin B, miconazole, and ketoconazole MICs were low for only a few.

Journal: :current medical mycology 0
partha bhattacharjee nh-rabindranath tagore international institute of cardiac sciences 124, e. m. bypass, mukundapur, kolkata–700099, west bengal, india

background and purpose: the incidence of fungal infection as well as candidemia has increased significantly, contributing to morbidity and mortality in the developed countries. the alarming increase in infections with multidrug resistant bacteria is due to overuse of a broad spectrum antimicrobials, which leads to over growth of candida spp.; thus, enhancing its opportunity to cause the disease...

2006
Sun Hee Park Su-Mi Choi Dong-Gun Lee Jung-Hyun Choi Jin-Hong Yoo Woo-Sung Min Wan-Shik Shin

BACKGROUND Amphotericin B dexoycholate is currently the standard empirical antifungal therapy for neutropenic patients with hematologic malignancies and who also have persistent fever that does not respond to antibacterial therapy. The antifungal triazoles offer a potentially safer and effective treatment alternative to Amphotericin B dexoycholate. METHODS We assessed the efficacy and safety ...

2014

Ketoconazole is no longer available for clinical determination of worst-case victim drug-drug interaction (DDI) potential for cytochrome P450 3A (CYP3A)-substrate drugs; clarithromycin and itraconazole are the proposed replacements. Ketoconazole DDIs are described by unbound systemic exposures due to absence of carrier-facilitated hepatic uptake, but this aspect of clarithromycin and itraconazo...

2014

Ketoconazole is no longer available for clinical determination of worst-case victim drug-drug interaction (DDI) potential for cytochrome P450 3A (CYP3A)-substrate drugs; clarithromycin and itraconazole are the proposed replacements. Ketoconazole DDIs are described by unbound systemic exposures due to absence of carrier-facilitated hepatic uptake, but this aspect of clarithromycin and itraconazo...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید